ELTP offers a cash-rich, low-multiple specialty generic platform with pipeline upside, but Vyvanse price erosion and distributor concentration make it a speculative asymmetric bet.
Overview
Elite Pharmaceuticals is a specialty generic drug company operating a cGMP- and DEA-registered facility in Northvale, New Jersey, with a niche position in controlled CNS stimulants, pain management and bariatrics. Its structural transformation from licensing to direct distribution under the Elite Laboratories label lifted direct sales to approximately 44% of FY2026 revenue and helped revenue reach $148.9 million, gross margin 50.4% and operating income $49.1 million. **The investment case depends on whether this direct model can offset rapid generic price erosion.** Q1 FY2027 exposed the risk: revenue fell 19.5% year over year to $32.4 million and operating income dropped 65% to $7.5 million as generic Vyvanse pricing normalized. The balance sheet remains unusually strong for an OTCQB microcap, with $29.8 million of cash, $95 million of working capital and only $4.7 million of long-term debt. Valuation is modest at 10.95x trailing normalized P/E and 7.55x EV/EBITDA, but the market discounts FY2026 earnings sustainability. Methadone, Requip XL, an anticoagulant ANDA, an anticonvulsant filing and potential Nasdaq up-listing are the principal catalysts. The five-year probability-weighted target is $0.50 versus $0.36 currently, implying 38.9% upside, but with highly asymmetric execution and concentration risks.